How Has the Myeloproliferative Disorders Drugs Market Evolved Historically and What is its Current Size?
The myeloproliferative disorders drugs market has seen considerable growth due to a variety of factors.
•In recent times, the myeloproliferative disorders drugs market has been consistently expanding. The market size is projected to rise from $9.47 billion in 2024 to $9.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 4.8%.
This positive trajectory in the historical period is credited to a rise in the occurrence of myeloproliferative disorders, progress in deciphering disease processes, advancements in clinical research and drug development, enhanced diagnostic and screening methods, as well as increased patient advocacy and awareness.
What is the Forecasted Market Size and CAGR for the Myeloproliferative Disorders Drugs Market?
The myeloproliferative disorders drugs market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for drugs treating myeloproliferative disorders is anticipated to witness consistent growth. It is projected to reach "$11.73 billion in 2029, with a compound annual growth rate (CAGR) of 4.3%.
This growth during the forecast period can be linked to factors such as the aging populace, advances in precision medicine, the introduction of new treatments, a global emphasis on rare diseases, government strategies, and healthcare policies. Key trends during this forecast period include the application of precision medicine techniques, clinical trials of experimental therapies, improved management of symptoms, increased utilization of ruxolitinib, and a focus on disease biomarkers.
What Are The Key Drivers Fueling Growth In The Myeloproliferative Disorders Drugs Market?
The increasing number of myeloproliferative disorder cases is anticipated to boost the expansion of the myeloproliferative disorder drug market. Myeloproliferative disorders are a range of diseases typified by the growth of one or more blood cell types in the peripheral blood, distinct from acute leukemia. The uptick in these disorders is predominantly attributed to genetic diseases, excess exposure to radiation, electrical wiring, or chemicals, and the elderly population. Drugs for myeloproliferative conditions impede the BCR-ABL protein through latching onto the ATP pocket in the active site, thereby inhibiting the subsequent phosphorylation of the target protein, facilitating the treatment of the myeloproliferative disorder. For instance, as reported by the US-based National Institute of Health in August 2022, in 2022, chronic myelogenous leukemia was more prevalent in males with an incidence rate of approximately 2.4 new cases per 100,000 compared to 1.4 new cases per 100,000 in females, versus 1.7 new cases per 100,000 in both genders per annum in 2020. Thus, the escalating incidence of myeloproliferative disorders is fueling the growth of the myeloproliferative disorders drug market.
What Are The Principal Market Segments In The Global Myeloproliferative Disorders Drugs Industry?
The myeloproliferative disorders drugs market covered in this report is segmented –
1) By Type: Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)
2) By Drug Type: JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Stores, Drug Stores
Subsegments:
1) By Primary Myelofibrosis: JAK Inhibitors, Immunomodulatory Agents, Supportive Care
2) By Polycythemia Vera (PV): JAK Inhibitors, Hydroxyurea, Phlebotomy, Interferon-alpha
3) By Essential Thrombocythemia (ET): JAK Inhibitors, Hydroxyurea, Anagrelide, Interferon-alpha
4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors, Corticosteroids, Interferon-alpha
5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors, Corticosteroids, Antihistamines, Immunotherapy
Pre-Book The Myeloproliferative Disorders Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Myeloproliferative Disorders Drugs Sector?
The development of innovative products is becoming an influential trend in the myeloproliferative disorder drug market. Major industry players are focusing their efforts on introducing groundbreaking products to solidify their position in this market. As an example, GSK PLC, a pharmaceutical and biotech firm based in the UK, received FDA endorsement in September 2023 for momelotinib, a treatment for primary myelofibrosis, a form of myeloproliferative disorder (MPD). This potentially innovative drug acts uniquely by obstructing three critical signaling pathways: the activin A receptor type I (ACVR1), Janus kinase (JAK) 1, and JAK2. This obstruction of JAK1 and JAK2 pathways can mitigate splenomegaly and constitutional symptoms. Moreover, the direct inhibiting of ACVR1 results in the reduction of circulating hepcidin, which is usually amplified in myelofibrosis and contributes to anemia.
Who Are the Key Players in the Myeloproliferative Disorders Drugs Market?
Major companies operating in the myeloproliferative disorders drugs market include:
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Incyte Corporation
• Eli Lilly and Co
• F Hoffmann-La Roche Ltd.
• Mylan NV
• Fresenius Kabi AG
• Hikma Pharmaceuticals plc
• GSK plc
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International Gmbh
• Sanofi Aventis Inc.
• AstraZeneca AB
• Apotex Inc
• Celgene Co.
• Gamida Cell Ltd.
• Geron Co.
• Promedior Inc.
• Johnson & Johnson Private Limited
• AbbVie Inc.
• AOP Orphan Pharmaceuticals AG
• Astellas Pharma Inc.
• Biogen Inc.
• Daiichi Sankyo Chemical Pharma Co. Ltd.
• Eisai Pharmaceuticals India Pvt. Ltd.
What are the Regional Insights into the Myeloproliferative Disorders Drugs Market?
North America was the largest region in the myeloproliferative disorder drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
